Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBIT: 2019-2024

Historic EBIT for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Dec 2024 value amounting to $190.8 million.

  • Harmony Biosciences Holdings' EBIT rose 6.12% to $65.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.6 million, marking a year-over-year increase of 28.72%. This contributed to the annual value of $190.8 million for FY2024, which is 0.63% down from last year.
  • Per Harmony Biosciences Holdings' latest filing, its EBIT stood at $190.8 million for FY2024, which was down 0.63% from $192.0 million recorded in FY2023.
  • Over the past 5 years, Harmony Biosciences Holdings' EBIT peaked at $192.0 million during FY2023, and registered a low of $17.0 million during FY2020.
  • Over the past 3 years, Harmony Biosciences Holdings' median EBIT value was $190.8 million (recorded in 2024), while the average stood at $167.7 million.
  • Per our database at Business Quant, Harmony Biosciences Holdings' EBIT spiked by 415.29% in 2021 and then dropped by 0.63% in 2024.
  • Harmony Biosciences Holdings' EBIT (Yearly) stood at $17.0 million in 2020, then skyrocketed by 415.29% to $87.5 million in 2021, then spiked by 37.31% to $120.2 million in 2022, then surged by 59.78% to $192.0 million in 2023, then dropped by 0.63% to $190.8 million in 2024.